



NVTH Symposium – April 10-11, 2019  
Golden Tulip Hotel Westduin – Koudekerke, Zeeland

**Wednesday April 10<sup>th</sup>, 2019**

11.30 – 12.30 Registration and Lunch

12.30 – 13.00 **Keynote Lecture I**  
Prof. Gijsje Koenderink (Amolf) '*Physical Properties of Fibrin*'  
Moderator: Moniek de Maat (EMC)

13.00 – 14.00 **Session I. Biochemistry of hemostasis**  
Moderators: Elisa D'Alessandro (CARIM) & Tom Plug (Sanquin)

**THE N-TERMINAL FIBRONECTIN TYPE II DOMAIN OF FACTOR XII ENSURES ZYMOGEN QUIESCENCE**

Chantal C. Clark, Z.L.M. Hofman, L. den Braven, S. de Maat, C. Maas. University Medical Center Utrecht, Department of Clinical Chemistry and Haematology

**FROM AUTOANTIBODIES TO THERAPEUTICS: EN ROUTE NOVEL TREATMENT FOR IMMUNE TTP**

Bogac Ercig<sup>1,2,3</sup>, J. Hrdinova<sup>1,2,3</sup>, N.A.G. Graca<sup>2,4</sup>, A. Gijsbers<sup>5</sup>, K. Wichapong<sup>1</sup>, D. Suylen<sup>1</sup>, P.H.P. Kaijen<sup>2</sup>, R.B.G. Ravelli<sup>5</sup>, P.J. Peters<sup>5</sup>, T.M. Hackeng<sup>1</sup>, K. Vanhoorelbeke<sup>6</sup>, C. Reutelingsperger<sup>1,3</sup>, Jan Voorberg<sup>2</sup>, G.A.F. Nicolaes<sup>1,3</sup>. <sup>1</sup>Dept. of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, <sup>2</sup>Dept. of Molecular and Cellular Hemostasis, Sanquin-AMC Landsteiner Laboratory, Amsterdam, <sup>3</sup>PharmaTarget, Maastricht, <sup>4</sup>Icosagen Cell Factory OÜ, Ülenurme vald, Tartumaa, Estonia, <sup>5</sup>The Maastricht Multimodal Molecular Imaging Institute, Maastricht University, <sup>6</sup>Laboratory for Thrombosis Research, IRF Life Sciences, KU Leuven, Kortrijk, Belgium.

**THE PSEUDONAJA TEXTILIS FACTOR V A2 DOMAIN C-TERMINUS MEDIATES LIPID-INDEPENDENT COFACTOR ACTIVITY AND FUNCTIONAL ACTIVATED PROTEIN C RESISTANCE**

Mark Schreuder, K.L. Cheung, P.H. Reitsma, M.H.A. Bos. Div. of Thrombosis and Hemostasis, Eindhoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden.

**PLATELET INTEGRIN  $\alpha_{IIb}\beta_3$  AND PHOSPHATIDYLSERINE ARE VITAL IN EXTRACELLULAR VESICLE RELEASE FROM ACTIVATED PLATELETS**

Alexandra C.A. Heinzmann<sup>1</sup>, T. Vajen<sup>1</sup>, M.F.A. Karel<sup>1</sup>, D.M. Coenen<sup>1</sup>, N.M.M. Meulendijks<sup>2</sup>, D.P.L. Suylen<sup>1</sup>, J.M.E.M. Cosemans<sup>1</sup>, J.W.M. Heemskerk<sup>1</sup>, T.M. Hackeng<sup>1</sup>, R.R. Koenen<sup>1</sup>. <sup>1</sup>Dept. of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, <sup>2</sup>The Netherlands Organisation for Applied Scientific Research (TNO), Material Solutions, Eindhoven.

14.00 – 14.05 **Poster Pitches I. Clinical research**  
Moderator: Mettine Bos (LUMC)

<u>Carolina E. Touw</u> (LUMC)	THROMBIN GENERATION IN PATIENTS ...
<u>Ferdows Atiq</u> (EMC)	BMI IS AN IMPORTANT DETERMINANT ...
<u>Ingrid Bistervels</u> (AMC)	MANAGEMENT OF ANTICOAGULANT THERAPY ...
<u>Wobke van Dijk</u> (UMCU)	THE INFLUENCE OF THROMBOPOIETIN-RECEPTOR AGONISTS ...
<u>Biröl Batman</u> (UMCU)	AGONIST-INDUCED PLATELET FUNCTION IN ...

14.05 – 14.30 **Coagulation Quiz**  
Quiz Masters: Henri Spronk (MUMC) & Joost Meijers (Sanquin)



NVTH Symposium – April 10-11, 2019  
Golden Tulip Hotel Westduin – Koudekerke, Zeeland

14.30 – 15.00 Coffee/Tea break

15.00 – 15.30 **Keynote Lecture II**

Prof. Tom Würdinger (Amsterdam UMC-VU) *'Tumor-educated Platelet RNA as Biomarker for the Detection of Lung Cancer'*  
Moderator: Judith Cosemans (CARIM)

15.30 – 16.30 **Session II. Coagulation: translational studies**

Moderators: Marijke Kuijpers (CARIM) & Jeroen Buijs (LUMC)

**TUMOR-DERIVED FACTOR VII ASSOCIATES WITH SURVIVAL AND REGULATES TUMOR PROGRESSION IN BREAST CANCER**

Chantal Kroone, C. Tiekens, M.Y. Kapteijn, J.T. Buijs, H.H. Versteeg. Div. of Thrombosis and Hemostasis, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden.

**THE OTTAWA SCORE DOES NOT PREDICT RECURRENT VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: RESULTS FROM THE HOKUSAI-VTE CANCER STUDY**

Floris Bosch<sup>1,2</sup>, N. van Es<sup>2</sup>, M. Di Nisio<sup>3</sup>, M. Carrier<sup>4</sup>, A. Segers<sup>5</sup>, M.A. Grosso<sup>6</sup>, F.I. Mulder<sup>2</sup>, J.I. Weitz<sup>7</sup>, G.E. Raskob<sup>8</sup>, H.R. Buller<sup>2</sup>. <sup>1</sup>Dept. of Internal Medicine, Tergooi Hospitals, Hilversum, <sup>2</sup>Dept. of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC-AMC, Amsterdam, <sup>3</sup>Dept. of Medicine and Ageing Sciences, Gabriele D'Annunzio University, Chieti, Italy, <sup>4</sup>Dept. of Medicine, Ottawa Hospital Research Institute, Ottawa, Canada, <sup>5</sup>ITREAS, Academic Research Organization, Amsterdam, <sup>6</sup>Clinical Development, Daiichi Sankyo Pharma Development, Basking Ridge, USA, <sup>7</sup>McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, Canada, <sup>8</sup>College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, USA.

**SLC44A2 DEFICIENT MICE EXHIBIT LESS SEVERITY OF THROMBOSIS IN A STENOSIS MODEL OF DVT**

Julia Tilburg<sup>1</sup>, C.X. Maracle<sup>1</sup>, P.E. Morange<sup>2,3</sup>, B.J.M. van Vlijmen<sup>1</sup>, G.M. Thomas<sup>2</sup>. <sup>1</sup>Div. of Thrombosis and Hemostasis, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, <sup>2</sup>Aix-Marseille Univ., INSERM, INRA, C2VN, Marseille, France, <sup>3</sup>APHM, CHU de la Timone, Laboratoire d'Hématologie, Marseille, France.

**THE INTESTINAL MICROBIOME AFFECTS THROMBIN GENERATION IN HUMAN SUBJECTS THROUGH EFFECTS ON COAGULATION RELATED PLASMA PROTEIN LEVELS**

Thijs E. van Mens<sup>1\*</sup>, Y. Mohammed<sup>2,3\*</sup>, R.S. Kootte<sup>1</sup>, W.F. Kopatz<sup>1</sup>, Christoph Borchers<sup>3</sup>, H.R. Buller<sup>1</sup>, H.H. Versteeg<sup>4</sup>, M. Nieuwdorp<sup>1,5</sup>. <sup>1</sup>Dept. of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC-AMC, Amsterdam, <sup>2</sup>Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, <sup>3</sup>UVic-Genome BC Proteomics Centre, University of Victoria, Victoria, BC, Canada, <sup>4</sup>Div. of Thrombosis and Hemostasis, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, <sup>5</sup>Dept. of Internal Medicine, Amsterdam Diabetes Center, Amsterdam UMC, Amsterdam, \*equal contribution.

16.30 – 16.35 **Poster Pitches II. Basic research**

Moderator: Ton Lisman (UMCG)

<u>Annemiek Dickhout</u>	(CARIM)	CCL5 AND CXCL4 ARE RAPIDLY INTERNALIZED ...
<u>Danique van den Kerkhof</u>	(CARIM)	DISAGREGIN: A POSSIBLE NEW $\alpha_{IIb}\beta_3$ INTEGRIN INHIBITOR ...
<u>Sanne Brouns</u>	(CARIM)	ENDOTHELIAL-BASED CONTROL OF ...
<u>Judith de Vries</u>	(EMC)	FIBRIN CLOTS CONTAINING NETS ...
<u>Awital Bar Barroeta</u>	(Sanquin)	HYDROGEN-DEUTERIUM EXCHANGE (HDX) ...



NVTH Symposium – April 10-11, 2019  
Golden Tulip Hotel Westduin – Koudekerke, Zeeland

- 16.35 – 17.35      **Van Creveld Lecture**  
Prof. Marcel Levi (UCL, UK) '*Personalised Medicine in Thrombosis and Haemostasis*'  
Moderator: Saskia Middeldorp (Amsterdam UMC-AMC)
- 17.35 – 18.35      **Poster Sessions: Basic and Clinical** + Drinks, Snacks
- 18.35 – 18.45      Presentation Results Quiz + NVTH Awards  
Moderators: Saskia Middeldorp & Mettine Bos (LUMC)
- 19.00                Dinner and party at Kontiki (beach)



NVTH Symposium – April 10-11, 2019  
Golden Tulip Hotel Westduin – Koudekerke, Zeeland

**Thursday April 11<sup>th</sup>, 2019**

07.30 – 09.00 Breakfast

09.00 – 09.30 **Keynote Lecture III**  
Dr. Ruben Bierings (Erasmus MC) *'Exocytosis of Weibel-Palade Bodies: How to Unpack a Vascular Emergency Kit'*  
Moderator: Jeroen Eikenboom (LUMC)

09.30 – 10.30 **Session III. Basic VWF and clinical bleeding**  
Moderators: Iris Kreft (Sanquin) & Lize van Vulpen (UMCU)

**SEC22B-DEPENDENT TRAFFICKING IS ESSENTIAL FOR VWF MULTIMERIZATION AND FORMATION OF ELONGATED WPBS**

Ellie Karampini<sup>1</sup>, J. Olins<sup>1</sup>, D. Geerts<sup>2</sup>, J. Voorberg<sup>1,3</sup>, Ruben Bierings<sup>1,4</sup>. <sup>1</sup>Molecular and Cellular Hemostasis, Sanquin Research and Landsteiner Laboratory, Amsterdam, <sup>2</sup>Medical Biology, <sup>3</sup>Experimental Vascular Medicine, Amsterdam UMC-AMC, Amsterdam, <sup>4</sup>Hematology, Erasmus University Medical Center, Rotterdam.

**IN VITRO AND IN VIVO AMELIORATION OF THE VON WILLEBRAND DISEASE TYPE 2B PHENOTYPE USING AN ALLELE-SPECIFIC siRNA**

Annika de Jong<sup>1</sup>, C. Casari<sup>2</sup>, R.J. Dirven<sup>1</sup>, B.J.M van Vlijmen<sup>1</sup>, P.J. Lenting<sup>2</sup>, C.V. Denis<sup>2</sup>, H.C.J. Eikenboom<sup>1</sup>. <sup>1</sup>Div. of Thrombosis and Hemostasis, Eindhoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, <sup>2</sup>HITH, UMR\_S1176, INSERM, Univ. Paris-Sud, Le Kremlin-Bicêtre Cedex, France.

**QUANTIFICATION OF VWF PROPEPTIDE RELEASE BEFORE AND AFTER DESMOPRESSIN IN VON WILLEBRAND DISEASE AND HEMOPHILIA A**

Jessica Heijdra<sup>1</sup>, R. Dirven<sup>2</sup>, M. Kruijff<sup>3</sup>, F. Leebeek<sup>3</sup>, J. Eikenboom<sup>2</sup>, M. Cnossen<sup>1</sup>. <sup>1</sup>Dept. of Pediatric Hematology, Erasmus University Medical Center-Sophia Children's Hospital, Rotterdam, <sup>2</sup>Div. of Thrombosis and Hemostasis, Eindhoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, <sup>3</sup>Dept. of Hematology, Erasmus University Medical Center, Rotterdam.

**IDEAL BODY WEIGHT IS PROVEN MOST RELIABLE TO DOSE FACTOR VIII CONCENTRATE IN OVERWEIGHT AND OBESE HEMOPHILIA A PATIENTS**

Iris van Moort<sup>1</sup>, T. Preijers<sup>2</sup>, H.C.A.M. Hazendonk<sup>1</sup>, R.E.G. Schutgens<sup>3</sup>, B.A.P. Laros-van Gorkom<sup>4</sup>, L. Nieuwenhuizen<sup>5</sup>, F.J.M. van der Meer<sup>6</sup>, K. Fijnvandraat<sup>7</sup>, F.W.G. Leebeek<sup>8</sup>, K. Meijer<sup>9</sup>, R.A.A Mathôt<sup>2</sup>, M.H. Cnossen<sup>1</sup>, for the "OPTI-CLOT" study group. <sup>1</sup>Dept. of Pediatric Hematology, Erasmus University Medical Center-Sophia Children's Hospital, Rotterdam, <sup>2</sup>Hospital Pharmacy-Clinical Pharmacology, Amsterdam UMC, Amsterdam, <sup>3</sup>Van Creveldkliniek, University Medical Center Utrecht, Utrecht, <sup>4</sup>Dept. of Hematology, Radboud University Medical Center, Nijmegen, <sup>5</sup>Dept. of Internal Medicine, Maxima Medical Center, Eindhoven, <sup>6</sup>Div. of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, <sup>7</sup>Dept. of Pediatric Hematology, Amsterdam UMC, Amsterdam, <sup>8</sup>Dept. of Hematology, Erasmus University Medical Center, Rotterdam, <sup>9</sup>Dept. of Hematology, University Medical Center Groningen, Groningen.

10.30 – 11.00 Coffee / Tea Break

11.00 – 11.30 **Keynote Lecture IV**  
Dr. Gerry Nicolaes (CARIM) *'From lab finding to spin-off asset'*  
Moderator: Coen Maas (UMCU)



NVTH Symposium – April 10-11, 2019  
Golden Tulip Hotel Westduin – Koudekerke, Zeeland

11.30 – 12.30

**Session IV: Clinical bleeding and thrombosis**

Moderators: Stan van der Beelen (CARIM) & Marjon Crossen (EMC)

**MANAGEMENT AND OUTCOME OF BLEEDING COMPLICATIONS IN PATIENTS TREATED WITH DIRECT ORAL ANTICOAGULANTS – UPDATED INTERIM ANALYSIS**

Roisin Bavalia<sup>1</sup>, R. Abdoellakhan<sup>2</sup>, E. Hamulyák<sup>1</sup>, M. Brekelmans<sup>1</sup>, B. Hutten<sup>3</sup>, H.J. Brinkman<sup>4</sup>, P. Westerweel<sup>5</sup>, R. Olie<sup>6</sup>, H. ten Cate<sup>6</sup>, M. Kruip<sup>7</sup>, S. Middeldorp<sup>1</sup>, K. Meijer<sup>2</sup>, M. Coppens<sup>1</sup>. <sup>1</sup>Dept. of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC-AMC, Amsterdam, <sup>2</sup>Dept. of Hematology, University Medical Center Groningen, Groningen, <sup>3</sup>Dept. of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC-AMC, Amsterdam, <sup>4</sup>Dept. of Molecular and Cellular Hemostasis, Sanquin Research, Amsterdam, <sup>5</sup>Dept. of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, <sup>6</sup>Dept. of Internal Medicine, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, <sup>7</sup>Dept. of Hematology, Erasmus University Medical Center, Rotterdam.

**POSTPARTUM HEMORRHAGE IN WOMEN WITH VON WILLEBRAND DISEASE AND CARRIERS OF HEMOPHILIA: A RETROSPECTIVE ANALYSIS**

Marieke C. Punt<sup>1</sup>, F.J. van Leusden<sup>1</sup>, J.L. Saes<sup>2,3</sup>, E. Mauser-Bunschoten<sup>1</sup>, M.H.E. Driessens<sup>4</sup>, E. Blasse<sup>5</sup>, S. Haitjema<sup>5</sup>, W.W. Solinge<sup>5</sup>, K.W.M. Bloemenkamp<sup>6</sup>, R.E.G. Schutgens<sup>1</sup>, A.T. Lely<sup>6</sup>, S.E.M. Schols<sup>2,3</sup>, K.P.M. van Galen<sup>1</sup>. <sup>1</sup>Van Creveldkliniek, University Medical Center Utrecht, Utrecht, <sup>2</sup>Dept. of Hematology, Radboud University Medical Center, Nijmegen, <sup>3</sup>Hemophilia Treatment Center, Nijmegen-Eindhoven-Maastricht, <sup>4</sup>Netherlands Hemophilia Patient Society, Nijkerk, <sup>5</sup>Laboratory of Clinical Chemistry and Hematology, <sup>6</sup>Dept. of Gynecology and Obstetrics, University Medical Center Utrecht, Utrecht.

**ASPIRIN OR HEPARIN OR BOTH FOR IMPROVING PREGNANCY OUTCOMES IN WOMEN WITH PERSISTENT ANTIPHOSPHOLIPID ANTIBODIES AND RECURRENT PREGNANCY LOSS**

Eva N. Hamulyák<sup>1</sup>, L.J.J. Scheres<sup>1,2</sup>, M.C. Marijnen<sup>1</sup>, M. Goddijn<sup>3</sup>, S. Middeldorp<sup>1</sup>. <sup>1</sup>Dept. of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC-AMC, Amsterdam, <sup>2</sup>Dept. of Clinical Epidemiology, Leiden University Medical Center, Leiden, <sup>3</sup>Amsterdam Reproduction and Development, Obstetrics and Gynaecology, Center for Reproductive Medicine, Amsterdam UMC-AMC, Amsterdam.

**THE ADDED VALUE OF ANTI-CARDIOLIPIN AND ANTI- $\beta$ 2GLYCOPROTEIN I IGM ANTIBODIES IN THE ANTIPHOSPHOLIPID SYNDROME, A EUROPEAN MULTICENTER STUDY**

Walid Chayoua<sup>1,2</sup>, H. Kelchtermans<sup>1,2</sup>, G.W. Moore<sup>3</sup>, J.C. Gris<sup>4</sup>, J. Musiał<sup>5</sup>, D. Wahl<sup>6</sup>, Bas de Laat<sup>1,2</sup>, K.M.J. Devreese<sup>7</sup>. <sup>1</sup>Cardiovascular Research Institute Maastricht (CARIM), <sup>2</sup>Synapse Research Institute, Maastricht, <sup>3</sup>Dept. of Haemostasis and Thrombosis, Viapath Analytics, Guy's & St. Thomas' Hospitals, London, UK, <sup>4</sup>Centre Hospitalier Universitaire de Nîmes et Université de Montpellier, France and Ivan Sechenov First Moscow State Medical University, Moscow, Russia, <sup>5</sup>Dept. of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland, <sup>6</sup>Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Centre Hospitalier Régional Universitaire de Nancy, Université de Lorraine, Inserm, DCAC, Nancy, France, <sup>7</sup>Coagulation Laboratory, Dept. of Diagnostic Sciences, Ghent University Hospital, Ghent, Belgium.

12.30 – 13.30

Lunch

13.30 – 14.00

NVTH Annual meeting

14.00 – 14.30

**Keynote Lecture V**

Dr. Heleen van Ommen (Erasmus MC) *'Pediatric Thrombosis: Past, Present, Future'*

Moderator: Pieter Willem Kamphuisen (Tergooi/UMCG)



NVTH Symposium – April 10-11, 2019  
Golden Tulip Hotel Westduin – Koudekerke, Zeeland

14.30 – 15.30

**Session V. Clinical thrombosis**

Moderators: Frits Mulder (Amsterdam UMC-AMC) & Astrid van Hylckama Vlieg (LUMC)

**ADHERENCE TO DIRECT ORAL ANTICOAGULANT TREATMENT FOR ATRIAL FIBRILLATION IN THE NETHERLANDS: A SURVEILLANCE STUDY**

Denise van Ginkel-Zielinski<sup>1</sup>, N. van Rein<sup>1</sup>, M. Teichert<sup>2</sup>, F.A. Klok<sup>3</sup>, F.R. Rosendaal<sup>1</sup>, F.J.M. van der Meer<sup>3</sup>, M.V. Huisman<sup>3</sup>, S.C. Cannegieter<sup>1,3</sup>, W.M. Lijfering<sup>1</sup>. <sup>1</sup>Dept. of Clinical Epidemiology, <sup>2</sup>Dept. of Clinical Pharmacy & Toxicology, <sup>3</sup>Div. of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden.

**EFFECT OF SWITCHING FROM WELL-CONTROLLED VITAMIN K ANTAGONISTS TO A DIRECT ORAL ANTICOAGULANT FOR ATRIAL FIBRILLATION ON QUALITY OF LIFE: LITTLE TO GAIN**

Jasper H.A. van Miert<sup>1,2</sup>, H.A.M. Kooistra<sup>1,2</sup>, N.J.G.M. Veeger<sup>3</sup>, A. Westerterp<sup>2</sup>, M. Piersma-Wichers<sup>1,2</sup>, K. Meijer<sup>1</sup>. <sup>1</sup>Dept. of Haematology, <sup>2</sup>Certe Thrombosis Service, Groningen, <sup>3</sup>Dept. of Epidemiology, University Medical Center Groningen, Groningen.

**RIVAROXABAN TREATMENT IN AN ATRIAL FIBRILLATION GOAT MODEL**

Billy Scaf<sup>1</sup>, E. D'Alessandro<sup>2</sup>, D. Opačić<sup>1</sup>, J. Simons<sup>1</sup>, A. van Hunnik<sup>1</sup>, M. Kuiper<sup>1</sup>, J. Winters<sup>1</sup>, R. van Oerle<sup>2</sup>, H. ten Cate<sup>2</sup>, H. Spronk<sup>2</sup>, S. Verheule<sup>1</sup>, U. Schotten<sup>1</sup>. <sup>1</sup>Dept. of Physiology, <sup>2</sup>Dept. of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht.

**SEX-DIFFERENCES IN CIRCULATING NEUTROPHIL EXTRACELLULAR TRAPS (NETS) LEVELS AND STROKE RISK: A POPULATION-BASED STUDY**

Samantha J. Donkel<sup>1</sup>, F.J. Wolters<sup>2</sup>, J.W.R. van Soerland<sup>1</sup>, M.A. Ikram<sup>3</sup>, M.P.M. de Maat<sup>1</sup>. <sup>1</sup>Dept. of Hematology, <sup>2</sup>Dept. of Epidemiology, <sup>3</sup>Depts. of Epidemiology, Radiology, Neurology, Erasmus University Medical Center, Rotterdam.

15.30 – 16.00

Presentation Jeanne Stibbe bokaal and closure

Moderator: Mettine Bos (LUMC)